Table 2 Comparison of liver function test at baseline and after treatment, and side effects related to statin
From: High dose statin prophylaxis in cardiopulmonary bypass related surgery: clinical utility
Control arm (n = 15) | Investigation arm (n = 15) | P- Value | |
|---|---|---|---|
Liver function test (at baseline) | |||
Bilirubin, μmol/l | 11 ± 1.1 | 12 ± 2.1 | 0.153 |
ALP, IU/l | 80 ± 6.4 | 75 ± 5.3 | 0.858 |
ALT, IU/l | 36 ± 6.6 | 22 ± 4.8 | 0.806 |
γGT, IU/l | 24 ± 11.4 | 24 ± 8.1 | 0.403 |
Liver function test (after treatment) | |||
Bilirubin, μmol/l | 10 ± 2.0 | 13 ± 2.7 | 0.916 |
ALP, IU/l | 75 ± 5.0 | 87 ± 3.9 | 0.334 |
ALT, IU/l | 26 ± 2.9 | 28 ± 3.8 | 0.676 |
γGT, IU/l | 29 ± 6.1 | 23 ± 5.8 | 0.725 |
Side effects | |||
Rhabdomyolysis | 0 | 0 | -- |
GI Disturbances | 0 | 0 | -- |
Renal Impairment | 0 | 0 | -- |